There was no evidence of difference in Gleason score (p = 0.75), previous local treatment (p = 0.73), presence of pain (p = 1.0), prior treatment with ARSI (p = 0.45), presence of visceral metastases (p = 0.70), bone metastases (p = 0.34), lymph node metastases (p = 1.0) or median baseline PSA (p = 0.27) regarding HER2 status. This evidence concerns the gene ERBB2 and metastatic malignant neoplasm in the lymph nodes.